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Abstract: There is increasing recognition of circulating tumour DNA (ctDNA) as a non-invasive
alternative to tumour tissue for the molecular characterisation and monitoring of disease. Recent
evidence suggests that cancer-associated changes can also be detected in the DNA contained within
extracellular vesicles (EVs). As yet, there has been limited investigation into the relationship between
EV DNA and ctDNA, and no studies have examined the EV DNA of breast cancer patients. The
aim of this study was to use low-pass whole-genome sequencing to identify copy number variants
(CNVs) in serial samples of both ctDNA and EV DNA from a patient with breast cancer. Of the
52 CNVs identified in tumour DNA, 36 (69%) were detected in at least one ctDNA sample and 13
(25%) in at least one EV DNA sample. The number of detectable variants in ctDNA and EV DNA
increased over the natural history of the patient’s disease, which was associated with progression
to cerebral metastases. This case study demonstrates that, while CNVs are detectable in patient EV
DNA, ctDNA has greater sensitivity than EV DNA for serial monitoring of breast cancer.
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1. Introduction
Copy number variants (CNVs) are among the most prevalent genomic alterations
in breast cancer, with certain CNVs such as the amplification of ERBB2 or the loss of
heterozygosity at the BRCA1/2 loci associated with particular clinical phenotypes [1–3]. As
such, the detection of clinically relevant CNVs is of considerable prognostic and therapeutic
importance in breast cancer. Whole-genome sequencing (WGS) of patient tumours has
facilitated the discovery of a huge array of CNVs across the breast cancer genome; however,
molecular profiling of tumour tissue is limited by sampling bias, tumour heterogeneity
and lack of sample availability upon the emergence of metastatic lesions [1,4]. Accordingly,
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there is a need for a method that can encapsulate tumoural heterogeneity and monitor
tumour clonal dynamics throughout the course of a patient’s disease.
Circulating tumour DNA (ctDNA), small fragments of DNA that have been released
into the circulation by apoptotic tumour cells, represents a potential surrogate for tumour
tissue that can be sampled non-invasively to track clonal evolution and therapeutic response [4]. Low-pass WGS (LP-WGS) studies of ctDNA in breast cancer have determined
that CNVs associated with metastatic progression and treatment response can be observed
longitudinally throughout patient treatment [5,6]. Recent data have also indicated that
cancer-related CNVs can be detected in the DNA of cancer patient-derived extracellular
vesicles (EVs), which are membrane-bound vesicles released from a wide range of cells
including tumour cells via exocytosis or membrane budding [7–12]. Interestingly, EVs are
thought to be stable in the blood for up to 30 days, and the DNA within them is protected
from nuclease degradation by the vesicle lipid membrane, suggesting that the assessment
of EV DNA may be a promising alternative or complement to ctDNA for non-invasive
cancer diagnosis and monitoring [13–15]. However, the association between ctDNA and
EV DNA and the degree to which their copy number profiles reflect one another remains
unclear. Additionally, there have been no studies investigating the utility of EV DNA for
copy number profiling in breast cancer patients.
In this case study, we used LP-WGS to identify and compare CNVs in tumour tissue,
ctDNA and EV DNA from a patient with metastatic breast cancer. We hypothesised
that EV DNA contains CNVs present in the patient’s tumour and also reflects those in
patient ctDNA, and hence may be a potential source of breast cancer DNA for non-invasive
patient monitoring.
2. Experimental Section
2.1. Patient Samples
The work presented in this study was undertaken using matched samples of tumour
tissue and plasma from a patient with Stage IV breast cancer. The patient gave informed
written consent prior to participation in the study. Serial blood samples (×3) were collected
at routine clinical consultations in March, May and September 2016. Blood samples
(10–20 mL) were collected in ethylenediaminetetraacetic acid (EDTA) anticoagulant and
processed within 2 h of collection. The blood was separated by centrifugation at 1600× g
for 20 min and the plasma fraction clarified by centrifugation at 16,000× g for 10 min. The
supernatant was stored at −80 ◦ C until further use. Formalin-fixed paraffin-embedded
(FFPE) tumour tissue from surgical resection of tumours in April 2010, June 2014 and
December 2016 was obtained from the pathology archives at PathWest Laboratory Medicine,
Western Australia. All FFPE specimens were confirmed by an expert breast pathologist to
possess a tumour cell content ≥ 80%.
2.2. EV Isolation
EVs were isolated from plasma using ultracentrifugation. Plasma samples (6 mL)
were diluted 1/10 in phosphate-buffered saline (PBS) and centrifuged at 12,000× g for
45 min in the Optima L-90K Ultracentrifuge (Beckman Coulter, Lane Cove, Australia) to
pellet any cell debris and apoptotic bodies. The resulting supernatant was centrifuged
twice at 110,000× g for 90 min to pellet the EVs, which were resuspended in 100 µL PBS.
Validation of successful EV isolation using this approach was performed on representative
samples according to guidelines established by the International Society of Extracellular
Vesicles [16]. This involved the use of 3 distinct techniques to elucidate particle size,
yield and presence of common markers. A detailed methodology for each technique is
outlined below.
2.3. Immuno-Electron Microscopy
EVs resuspended in PBS (10 µL) were fixed in 2% paraformaldehyde and transferred
onto 200-mesh formvar–carbon-coated copper grids (ProSciTech, Kirwan, Australia). Sam-
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ples were adsorbed for 20 min at room temperature prior to being washed twice in filtered
PBS and 4 times in 50 mM glycine to quench free aldehyde groups. Samples were then
blocked in 5% bovine serum albumin (BSA) for 10 min before being incubated with primary
antibody solution (mouse anti-human CD9, clone MM2/57; 10 µg/mL, Merck, Bayswater,
Australia) for 30 min. Grids were then washed 4 times in 0.1% BSA and 4 times in 0.5%
BSA before incubation with secondary antibody (goat anti-mouse IgG-gold conjugate,
1:24, Aurion, Wageningen, The Netherlands) for 20 min. Labelled samples were washed 6
times in PBS, fixed in 1% glutaraldehyde and washed 6 times in deionised water before
counterstaining with 1% uranyl acetate. Following 2 min of counterstaining, grids were
left overnight to dry and then were visualised on the JEOL JEM-2100 electron microscope
(JEOL, Frenchs Forest, Australia) at an operating voltage of 120 kV. Images were captured
using an 11-megapixel Gatan Orius digital camera (Gatan, Abingdon, UK).
2.4. Nanoparticle Tracking Analysis
EV samples (100 µL) were diluted 1/100 in PBS and injected into the analysis chamber
of a NanoSight NS500 Instrument (Malvern Panalytical, Taren Point, Australia) for particle
size and concentration analysis. This instrument is equipped with a 405 nm laser and a
sCMOS camera to detect the Brownian motion of light-scattering particles as they move
through solution. Sample analysis was performed at a camera level of 10 and a gain of 250,
with a detection threshold of 10 pixels. Settings for blur, minimum track length and minimum expected size were set to ‘auto’. Videos were recorded for 60 s at 30 frames/second in
triplicate at 25 ◦ C. All post-acquisition settings remained constant between samples. NTA
software v3.0 (Malvern Panalytical, Taren Point, Australia) was used to process and analyse
the data. Each video was analysed to generate particle size (nm) distribution profiles and
concentration values (particles/mL solution), which were downloaded as a report with
the results of the quality control analysis. The raw observational data were exported into
Microsoft® Excel (Microsoft, Redmond, WA, USA) as comma-separated values (CSV) file.
2.5. Western Blot
EV samples and MDA-MB-231 breast cancer cells in 100 µL PBS were mixed with
100 µL of RIPA buffer (Sigma-Aldrich, North Ryde, Australia) and protease inhibitors
(Roche Diagnostics, North Ryde, Australia) and incubated on ice for 1 h to lyse the vesicle
membranes. EV and cell proteins were collected by centrifugation at 16,000× g for 15 min
at 4 ◦ C. The proteins were diluted in 4× Laemmli Buffer (Bio-Rad, Gladesville, Australia)
for a final loading volume of 20 µL. Proteins were separated at 155 V for 30 min on a
Mini Protean® TGX 5–15% Stain-Free™ Precast Gel (Bio-Rad) using the Mini Protean®
Tetra Cell (Bio-Rad). Proteins were then transferred onto a Trans-Blot® Turbo™ Mini
Nitrocellulose Membrane (Bio-Rad) using the Trans-Blot® Turbo™ Transfer System (BioRad) at a constant voltage of 25 V. The membrane was then probed for EV proteins using the
iBind™ Flex Western Device (Thermo Fisher Scientific, Scoresby, Australia), commencing
with blocking for 20 min in iBind™ Flex Solution (Thermo Fisher Scientific). Primary
antibody solutions of mouse anti-human CD9 (clone 1.3.3.22, Thermo Fisher Scientific),
mouse anti-human calnexin (clone 1563, Novus Biologicals, Littleton, CO, USA), and rabbit
anti-human TSG101 (clone EPR7130B, Abcam, Melbourne, Australia) were created, with
dilutions of 1:250 and 1:500 for anti-CD9 and calnexin/TSG101, respectively. Samples
were incubated with primary antibody solution before being incubated with secondary
antibodies (sheep anti-mouse IgG-HRP conjugate, 1:2000, GE Healthcare, Parramatta,
Australia; goat anti-rabbit IgG-HRP conjugate, 1:2000, Merck) for a combined run time of
2.5 h. Signals were developed using Clarity™ Western ECL Blotting Substrates (Bio-Rad)
and were subsequently imaged using the ChemiDoc™ Touch Imaging System (Bio-Rad).
Images were processed using Image Lab™ software v6.0 (Bio-Rad, Gladesville, Australia).
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2.6. DNA Extraction
EVs (50 µL) were treated with DNase I prior to DNA extraction to reduce the levels
of cell-free DNA, which was co-isolated along with the EVs. This was carried out with
the Ambion TURBO DNA-free DNA Removal Kit (Thermo Fisher Scientific, Scoresby,
Australia). DNA was extracted from DNase-treated EVs and from the remaining plasma
(2–4 mL) using the QIAamp Circulating Nucleic Acid Kit (Qiagen, Chadstone, Australia).
DNA was extracted from 10-micron sections of FFPE tissue with the GeneRead DNA FFPE
Kit (Qiagen). All protocols were performed as per the manufacturer’s instructions. DNA
was quantified with both the Qubit dsDNA HS Assay (Thermo Fisher Scientific) and the
Agilent High Sensitivity DNA Assay (Agilent Technologies, Mulgrave, Australia) and
stored at −20 ◦ C until further use.
2.7. Low-Pass Whole Genome Sequencing
DNA was sheared via sonication using the Covaris S2 Focused-ultrasonicator (Covaris,
Bankstown, Australia) for 40 s with duty cycles of 10,200 cycles per burst and an intensity of
5. Library preparation was performed with the NEBNext Ultra II DNA Library Preparation
Kit (New England Biolabs, Ipswich, MA, USA) as per the manufacturer’s instructions.
Library fragment size distribution was determined with the Agilent 4200 TapeStation
System (Agilent Technologies). Libraries were normalised, pooled and diluted to a final
concentration of 1.8 pM and sequenced with 75 base pair (bp) paired-end reads on the
Illumina NextSeq 500 platform (Illumina, Scoresby, Australia) up to a mean depth of 1×.
2.8. Data Analysis
Reads were aligned to hg19 with the Burrows–Wheeler Aligner-MEM software v0.7.15
following the removal of sequencing adaptors with Trim Galore software v0.4.5 (Babraham
Institute, Cambridge, UK) [17]. Variant calling was performed on the GATK 3.7 haplotype
caller (The Broad Institute, Cambridge, MA, USA). Metric summarisation and duplicate
identification were carried out using Picard tools v2.9.0 (The Broad Institute,). QDNASeq
software v1.19.0 (VU University Medical Centre, Amsterdam, The Netherlands) was used
to call the copy number variations, with no matched normal samples, the baseline ploidy
set at 2 and a fixed bin size of 15 kilobases (kb) [18]. A 2-tailed Student’s t-test was used to
determine whether there was a significant difference in EV DNA vs. ctDNA yield and in
the sequencing metrics of tumour DNA (tDNA), EV DNA and ctDNA samples. A p-value
of <0.05 was considered statistically significant.
3. Results
3.1. Patient Characteristics
The subject of this study was a 61-year-old female with Stage II invasive ductal carcinoma of the triple negative subtype, diagnosed in November 2009. The tumour was
surgically resected in April 2010 and the patient was treated with adjuvant chemotherapy (4 cycles of docetaxel and cyclophosphamide) and radiotherapy. Four years later
(June 2014), a chest wall lump was biopsied and shown to be metastatic breast cancer;
capecitabine was then commenced. In January 2015, a computed tomography (CT) scan
demonstrated mediastinal progression and oral vinorelbine was prescribed but did not
result in tumour reduction. By March 2015, the mediastinal mass had enlarged and mediastinal radiotherapy and gemcitabine treatment commenced, leading to a durable response.
The patient consented to the study in March 2016, whilst in remission, and blood samples
were then collected consecutively over a period of 7 months from March to September 2016.
Disease progression was noted in December 2016, with posterior cerebellar metastasis,
and—despite surgical excision—the patient died weeks later.
3.2. EV DNA vs. ctDNA Yield
EVs within the range of 30–600 nm (mean = 200 ± 30 nm) were identified, indicating
that samples contained an enrichment of small EVs (see Figure 1a). EVs were positive for
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(see Figure 2). This was also reflected in the circulating DNA samples, with 7 variants identified in ctDNA from Plasma 1, 23 in ctDNA Plasma 2 and 48 in ctDNA Plasma 3. EV DNA
Plasma 1 and Plasma 2 samples did not have any detectable variants, while Plasma 3 EV
DNA contained 13 CNVs. There were significantly more CNVs detected in tDNA samples
than in ctDNA or EV DNA samples (p = 0.04 and p < 0.01, respectively). Variants ranged
in size from 0.3 to 106.5 megabases (Mb; mean 20.0 Mb) and were distributed randomly
throughout the genome (i.e., they were not concentrated in particular chromosomes).
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Figure 2. Circos plot comparing copy number alterations detected in ctDNA, EV DNA and tDNA samples. Each track
illustrates the copy number across the genome in individual samples. Note that EV DNA samples 1 and 2 did not contain
detectable copy number variants (CNVs) and thus are not depicted. Tracks are divided into sections according to each
autosome, arranged clockwise from 1 to 22. The vertical scale of the tracks indicates the copy number at that region in the
genome. The scale is consistent across all tracks. The grey line in the middle of each track represents a normal copy number
of 2.0. CNVs are depicted by boxes coloured according to the type of alteration (see key). The horizontal length of the box
indicates the size of the region of altered copy numbers in megabases (scale on outer ideogram).

There were 52 individual regions of copy number variation, which were detected in
all tumour DNA samples, indicating that these were likely early ‘driver’ events (those
required for tumour growth and survival); these were present throughout patient treatment
(see Table S1 for a full list of copy number changes and associated genes detected in all
samples). Of these variants, 36 (69%) were detected in at least one sample of ctDNA and 13
(25%) were detected in EV DNA Plasma 3. There were two variants identified in ctDNA
that were not in the tDNA or EV DNA. All 13 variants in EV DNA were identified in the
tumoural DNA, but two were not found in the ctDNA.
4. Discussion
This case study has demonstrated that LP-WGS can identify CNVs in EV DNA as
well as in ctDNA, the first such observation for breast cancer. Importantly, several of these
CNVs have potential implications for prognosis and treatment. For example, patients with
both germline and somatic loss of heterozygosity at the BRCA1 locus (17q21) have been
shown to have improved responsiveness to platinum-based chemotherapies and sensitivity
to poly-ADP-ribose polymerase inhibitors, whilst also demonstrating selective resistance to
taxanes [3,20,21]. The number of detectable CNVs in patient ctDNA and EV DNA increased
over the time course and natural history of the disease, in keeping with disease progression
and associated clonal evolution. Emerging CNVs were detectable within both ctDNA and
EV DNA prior to clinical evidence of the cerebellar metastasis, suggesting that sequencing

1
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of circulating DNA may indicate disease progression at an earlier stage than conventional
clinical monitoring tools.
While this is a novel and potentially significant finding, CNVs were only detected
in one of the three EV DNA samples studied. EV DNA also had a considerably lower
sensitivity for tumour driver CNVs than ctDNA (25% vs. 69%, respectively). Technical
factors that may explain these differences in sensitivity include the very low yields (~5 ng
total) and fragmented nature of EV DNA. Future studies may attempt to overcome these
technical issues through the size selection of large EVs (>1000 nm), which have been shown
to contain more tumour-derived DNA than small EVs (<200 nm) [9,22]. Removing the
12,000 g ultracentrifugation step may increase the yield of large EVs and thus EV DNA.
Similarly, methods to enrich tumour-specific EV subpopulations (i.e., immunocapture)
would increase the tumour DNA signal over the wild-type background and may improve
sensitivity [23].
Furthermore, the copy number profiling method utilised does not include a matched
normal sample to normalise the copy number [18]. While this does increase the sensitivity
of the analysis by improving upon the level of background noise that would be generated
by running a reference sample, it also means that the algorithm cannot completely correct
for technical bias in read coverage [24]. As such, there is a higher margin for error in CNV
calling, which could explain why there were no CNVs called with confidence in EV DNA
Plasma 1 and Plasma 2 samples. There are many computational approaches to correct
for this source of variance; however, all of them rely on a comparison between tumour
and matched normal tissue and thus could not be applied in this case [25]. Follow-up
studies should therefore endeavour to include patient-matched germline DNA to increase
the confidence of copy number detection, as well as to enable the discrimination between
inherited and somatic variants, as this may have bearing on their clinical significance.
Biological differences between the release and distribution of ctDNA and EV DNA
may have also contributed to the observed disparities in the copy number profiles. Given
that the main mechanisms of ctDNA and EV release are through cell death and active
secretion, respectively, it is reasonable to hypothesise that these entities are released from
two distinct subpopulations of cells—i.e., ctDNA is shed from apoptotic tumour cells,
whereas EV DNA is actively secreted from viable neoplastic cells [26,27]. Because the
purpose of this study was to compare the copy number profiles of EV DNA and ctDNA,
a pre-extraction DNase treatment step was necessary to remove contaminating cell-free
DNA from EV DNA samples. However, future studies may exclude this step in order
to capture all DNA within EV preparations and maximize the likelihood of detecting a
tumour-specific change.
Discordance between plasma and tissue can be attributed to genetic heterogeneity
within and between tumours, as well as temporal disparities in sample collection [19]. In
this study, plasma was collected from the patient several years after the resection of the
primary tumour, during which time she received multiple lines of chemotherapy. As a
result, it is unsurprising that there were some variants detected in the primary tumour that
were not detected in the plasma, and vice versa. In addition, rates of ctDNA shedding can
impact the representation of molecular drivers within the plasma [28]. This disparity can be
exacerbated by the release of cell-free DNA from non-malignant cells (such as leucocytes),
which dilutes the tumour fraction within the blood and decreases the sensitivity for the
detection of rarer CNVs [29]. In this study, plasma processing was performed within
two hours of collection to reduce the possibility of contamination via leucocyte lysis.
Further optimisation of plasma collection and processing (i.e., using blood collection tubes
with specialised preservatives such as Streck Cell-Free DNA BCT® tubes) may lead to
improvements in CNV detection.
5. Conclusions
This case study is significant as it demonstrates that CNVs reflecting the tumour
genomic profile can be detected in both the ctDNA and EV DNA of a breast cancer patient.

Biomedicines 2021, 9, 14

8 of 9

However, while studies in other cancers suggest that EV DNA is a viable alternative to
ctDNA for genetic profiling and disease monitoring, we show that the sensitivity of EV
DNA for CNV detection is lower than that of ctDNA. This may be due to the quality
and quantity of EV DNA as well as biological factors, such as the cell of origin. As such,
further studies of EV DNA in breast cancer are required before any comment can be made
regarding the clinical applicability of this approach.
Supplementary Materials: The following are available online at https://www.mdpi.com/2227-905
9/9/1/14/s1, Table S1: Full list of genes located in regions of copy number change detected in each
tDNA, ctDNA and EV DNA sample.
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